Singapore markets closed

Straits Times Index
3,415.51
+47.61(+1.41%)
S&P 500
5,509.01
+33.92(+0.62%)
Dow
39,331.85
+162.33(+0.41%)
Nasdaq
18,028.76
+149.46(+0.84%)
Bitcoin USD
60,190.74
-2,279.72(-3.65%)
CMC Crypto 200
1,304.28
-30.63(-2.30%)

ITCI Dec 2025 60.000 put

OPR - OPR Delayed price. Currency in USD

Add to watchlist

8.50

0.00

(0.00%)

At close: 11:33AM EDT

Loading interactive chart…

Zacks
Intra-Cellular's (ITCI) Caplyta Boosts Sales, Dependence a Woe
Intra-Cellular (ITCI) is witnessing strong Caplyta sales, driven by an increasing prescription rate. However, the company is heavily dependent on Caplyta sales for growth, which is a concern.
Zacks
Biotech Stock Roundup: ITCI Up on Study Data, ZNTL, OVID Down on Updates & More News
Intra-Cellular Therapies (ITCI) and Zentalis Pharmaceuticals, Inc. (ZNTL) are in the spotlight following pipeline and regulatory updates, respectively.
Zacks
Intra-Cellular (ITCI) Up as Second Depression Study Meets Goals
Intra-Cellular (ITCI) gains 10% after achieving key goals in the second late-stage study evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of MDD.